| Ident. | Authors (with country if any) | Title |
|---|
| 002731 |
D. Cunningham [Royaume-Uni] ; B. Sirohi [Royaume-Uni] ; A. Pluzanska [Pologne] ; B. Utracka-Hutka [Pologne] ; J. Zaluski [Pologne] ; R. Glynne-Jones [Royaume-Uni] ; P. Koralewski [Pologne] ; J. Bridgewater [Royaume-Uni] ; P. Mainwaring [Australie] ; H. Wasan [Royaume-Uni] ; J.-Y. Wang [Taïwan] ; C. Szczylik [Pologne] ; P. Clingan [Australie] ; R. T. T. Chan [Hong Kong] ; I. Tabah-Fisch [France] ; J. Cassidy [Royaume-Uni] | Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer |
| 002859 |
E. Van Cutsem [Belgique] ; F. Rivera [Espagne] ; S. Berry [Canada] ; A. Kretzschmar [Allemagne] ; M. Michael [Australie] ; M. Dibartolomeo [Italie] ; M.-A. Mazier [France] ; J.-L. Canon [Belgique] ; V. Georgoulias [Grèce] ; M. Peeters [Belgique] ; J. Bridgewater ; D. Cunningham | Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study |
| 002A63 |
Thierry Andre [France, Italie, Espagne, Royaume-Uni, Australie] ; Corrado Boni ; Matilde Navarro ; Josep Tabernero ; Tamas Hickish ; Clare Topham ; Andrea Bonetti ; Philip Clingan ; John Bridgewater ; Fernando Rivera ; Aimery De Gramont | Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial |
| 004A20 |
Thierry Andre [France] ; Corrado Boni [Italie] ; Lamia Mounedji-Boudiaf [France] ; Matilde Navarro [Espagne] ; Josep Tabernero [Espagne] ; Tamas Hickish [Royaume-Uni] ; Clare Topham [Royaume-Uni] ; Marta Zaninelli [Italie] ; Philip Clingan [Australie] ; John Bridgewater [Royaume-Uni] ; Isabelle Tabah-Fisch [France] ; Aimery De Gramont [France] | Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer |
